Zynerba pharmaceuticals.

Sep 27, 2023 · 27 Sep, 2023, 08:00 ET. PLYMOUTH MEETING, Pa. , Sept. 27, 2023 /PRNewswire/ -- In connection with the previously announced merger agreement, Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq ... About Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders.Zynerba Pharmaceuticals Inc. Click to enlarge. On the fundamentals data we receive, we apply a proprietary algorithm to compute relative scores for categories like Growth, PEG, EPS and Revenue ...Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum …Track Zynerba Pharmaceuticals Inc (ZYNE) Stock Price, Quote, latest community messages, chart, news and other stock related information.

Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, and 22q11 ...Devon, PA, September 14, 2020 – Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today provided an update on its Fragile X syndrome (FXS) and developmental and epileptic encephalopathies (DEE) programs. Zynerba ...

Zynerba Pharmaceuticals Inc (Zynerba Pharmaceuticals), formerly AllTranz Inc, is a developer of next-generation synthetic cannabinoid therapeutics. The company produce transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company provides pipeline product candidates includes ZYN002.When it comes to transporting temperature-sensitive goods, such as food and pharmaceuticals, the reliability and expertise of the freight company can make all the difference. The first thing to consider when choosing a refrigerated freight ...

Shares of Zynerba Pharmaceuticals ( ZYNE) were crashing 18.3% lower as of 10:48 a.m. EDT on Wednesday after falling as much as 26.5% earlier in the morning. The big plunge came after Zynerba ...Aug 14, 2023 · Zynerba is a pharmaceutical company focused on the development of synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product pipeline consists of Zygel which is a ... About Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders.Harmony Biosciences to buy Zynerba Pharmaceuticals for up to $200 million. Shares of Zynerba Pharmaceuticals Inc. ZYNE, +0.89% jumped 300% premarket on Monday after Harmony Biosciences Holdings Inc. HRMY, -0.47% said it would acquire the cannabinoid therapy company in a deal...

18 Jan 2022 ... Zynerba Pharmaceuticals, Inc. - специализированная фармацевтическая компания. Компания занимается разработкой синтетических каннабиноидных ...

Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, and 22q11 ...

© 2023 Zynerba Pharmaceuticals, Inc. All rights reserved. 80 W. Lancaster Avenue, Suite 300 Devon, PA 19333 484.581.7505 As more states legalize the use of marijuana recreationally, companies such as Cara Therapeutics, Zynerba Pharmaceuticals, GW Pharmaceuticals and Insys Therapeutics will benefit, said Jason ...Interactive chart of historical net worth (market cap) for Zynerba Pharmaceuticals (ZYNE) over the last 10 years. How much a company is worth is typically ...Date: Nov. 6. Buyer: BioNTech. Price: N/A. BioNTech has been on a business development world tour in 2023, licensing a number of assets with a focus on oncology and antibody-drug conjugates in ...Zynerba Pharmaceuticals, Inc. Securities Litigation. May 28, 2021 Active Cases. Status The distribution checks have been mailed. Claims Filing Deadline July 30, 2021. Exclusion Deadline August 10, 2021. Objection Deadline August 10, 2021. Settlement Hearing August 31, 2021 at 1:30 p.m.1.15. Renaissance Technologies LLC. 1.12. CSS LLC. 0.88. The latest Zynerba Pharmaceuticals stock prices, stock quotes, news, and ZYNE history to help you invest and trade smarter.

Feb 15, 2022 · Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, and 22q11 ... About Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically produced, synthetic transdermal cannabidiol therapies for orphan neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome ...Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome and 22q11.2 deletion syndrome.Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome and 22q11.2 deletion syndrome.Zynerba Pharmaceuticals is now part of Harmony Biosciences and we look forward to continuing our mission on behalf of people living with FXS. The…. Liked by Terri Sebree. Celebrating ...Mission Statement of Zynerba Pharmaceuticals, Inc. (ZYNE) General Summary of Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company that is focused on developing and commercializing proprietary next-generation transdermally-delivered cannabinoid therapeutics for rare and near-rare …

Earnings for Zynerba Pharmaceuticals are expected to grow in the coming year, from ($0.84) to ($0.49) per share. Price to Earnings Ratio vs. the Market. The P/E ratio of Zynerba Pharmaceuticals is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, 22q11.2 deletion syndrome and autism ...

Oct 11, 2023 · Annual Meeting to Reconvene on August 25, 2023 at 9:00 a.m. EDT. Devon, PA, August 8, 2023 — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) (the “Company”), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the new date for the adjourned 2023 Annual Meeting of Stockholders (“Annual Meeting ... Existing American-style Zynerba Pharmaceuticals, Inc. options remain exercisable at the option of the Disclaimer This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility forSearch for ticker symbols for Stocks, Mutual Funds, ETFs, Indices and Futures on Yahoo!Oct 11, 2023 · Annual Meeting to Reconvene on August 25, 2023 at 9:00 a.m. EDT. Devon, PA, August 8, 2023 — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) (the “Company”), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the new date for the adjourned 2023 Annual Meeting of Stockholders (“Annual Meeting ... Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, and 22q11 ...May 15, 2023 · Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome and 22q11.2 deletion syndrome.

Zynerba’s mission is to develop next-generation transdermally-delivered cannabinoid therapeutics to help address significant unmet medical needs and improve the lives of patients with rare neuropsychiatric conditions such as Fragile X syndrome (FXS) and 22q11.2 deletion syndrome (22q).

Zynerba Pharmaceuticals has such a small amount of debt that we'll set it aside, and focus on the US$59m in cash it held at December 2020. Importantly, its cash burn was US$42m over the trailing ...

Trial will evaluate the efficacy and safety of Zygel in children and adolescents with Fragile X Syndrome Topline results expected in second half of 2023 DEVON, Pa., Sept. 13, 2021 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for …Nov 15, 2022 · Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, 22q11.2 deletion syndrome and autism spectrum ... Based on 3 Wall Street analysts offering 12 month price targets for Zynerba Pharmaceuticals in the last 3 months. The average price target is $1.11 with a high forecast of $1.11 and a low forecast of $1.11. The average price target represents a -14.62% change from the last price of $1.30. Highest Price Target $1.11. Average Price Target $1.11.Zynerba Pharmaceuticals. Zynerba Pharmaceuticals is a transdermal synthetic cannabinoid treatments.DEVON, Pa., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near ...Oct 4, 2023 · Devon, PA, October 4, 2023 — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today reminds all stockholders, including individual stockholders, to promptly tender their shares into the tender offer (the “Offer”) by Harmony Biosciences Holdings, Inc. (“Harmony ... Zynerba is an orphan-focused, neuropsychiatric, biopharmaceutical company taking a different and exciting transdermal approach to cannabinoids. Zynerba Pharmaceuticals has been acquired by Harmony Biosciences, a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases ... Devon, PA, September 29, 2023 — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today released the following letter to stockholders concerning the pending tender offer by Harmony Biosciences Holdings, Inc. (“Harmony”). …14 Aug 2023 ... HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC. Acquisition expands pipeline and diversifies portfolio to drive long-term growth.About Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically produced, synthetic transdermal cannabidiol therapies for orphan neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X …Aug 14, 2023 · About Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically produced, synthetic transdermal cannabidiol therapies for orphan neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome ...

Zynerba Pharmaceuticals, Inc. is primarily engaged in the pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. The Company is engaged in improving the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome (FXS), and chromosome 22q11.2 …Zynerba Pharmaceuticals, Inc. (ZYNE) is the subject of an Offer to Purchase (The “Offer”), as described below: Purchaser:Xylophone Acquisition Corporation, a wholly owned subsidiary of Harmony Biosciences Holdings, Inc. Security to be Purchased: Zynerba Pharmaceuticals, Inc. (ZYNE) Common SharesZynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023 . September 14, 2023 Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th …Oct 12, 2023 · Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for ... Instagram:https://instagram. kols stockbest 401k allocationdow predictionsautomated trading program A bunch of smaller companies that are developing cannabis-based drugs include Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) and Cara Therapeutics Inc (NASDAQ:CARA). Then there are some companies whose ... tesla predictionsip nyse Are you looking to sell your used lab equipment? Whether you are a research institution, a pharmaceutical company, or a laboratory owner, there comes a time when you need to upgrade your equipment and find a new home for the old ones. social media stocks Harmony Biosciences Holdings has agreed to acquire Zynerba Pharmaceuticals for up to $200 million in a deal involving two suburban Philadelphia life sciences companies. Zynerba's stock pice soared ...Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023 . September 14, 2023 Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th …